Disease Burden in Children With Spinal Muscular Atrophy: Results From a Large Cross-Sectional Study

Spencer Rosero1, Jennifer Weinstein1, Jamison Seabury1

  • 1Center for Health and Technology, 6927The University of Rochester, Rochester, NY, USA.

Journal of Child Neurology
|December 20, 2022
PubMed

Insights

This study highlights key symptoms in children with spinal muscular atrophy (SMA). Weakness in the hip, thigh, or knee significantly impacts quality of life, guiding future SMA therapeutic research.

Area of Science:

  • Pediatric Neuromuscular Disorders
  • Clinical Research
  • Patient-Reported Outcomes

Background:

  • Spinal muscular atrophy (SMA) is a rare genetic disorder affecting motor neurons.
  • Understanding symptom burden in pediatric SMA is crucial for therapeutic advancement.
  • Current research lacks comprehensive data on symptom impact and prevalence in children with SMA.

Purpose of the Study:

  • To identify and characterize the prevalence and impact of symptoms in children with spinal muscular atrophy (SMA).
  • To generate a comprehensive dataset on the disease burden experienced by pediatric SMA patients.
  • To inform and focus future therapeutic development for SMA.

Main Methods:

  • Qualitative interviews with 16 caregivers of children with SMA.
  • Development of a survey based on interviews, assessing 260 symptoms across 17 themes.
  • Survey completion by 77 caregivers of children with SMA (aged 4 months to 12 years).

Main Results:

  • Symptom prevalence in pediatric SMA correlates with SMA type, SMN2 gene copy number, and functional status.
  • Hip, thigh, or knee weakness reported as the most impactful symptom for children with SMA.
  • Identified a discrepancy between the most prevalent and most impactful symptoms in pediatric SMA.

Conclusions:

  • This study presents a large dataset on the disease burden in pediatric spinal muscular atrophy.
  • The most impactful symptoms for children with SMA are not necessarily the most prevalent.
  • Findings provide critical insights to guide targeted therapeutic development for SMA.